title: CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.
authors: Elena G
authors: EG
authors: Kamburova
authors: Hans J M P
authors: HJ
authors: Koenen
authors: Irma
authors: I
authors: Joosten
authors: Luuk B
authors: LB
authors: Hilbrands
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology*; D018941:Antigens, CD19 / Q000378:metabolism*; D018501:Antirheumatic Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D018501:Antirheumatic Agents